Abstract
Identification of genes and pathways that alter lifespan has allowed for new insights into factors that control the aging process as well as disease. While strong molecular links exist between aging and metabolism, we hypothesize that targeting the mechanisms involved in aging will also give rise to therapeutics that treat other devastating age-related diseases, such as neurodegeneration, cancer, inflammation and cardiovascular disease. Insulin sensitivity, glycemic control and adiposity are not only hallmarks of the major metabolic diseases, type 2 diabetes and obesity, but they also represent significant risk factors for the development of Alzheimers Disease and cognitive impairment. Insulin/IGF-1 signaling is an important pathway regulating aging and disease in a variety of species, including mammals. Here we describe an important role for the gut-derived peptide ghrelin in upstream signaling through the insulin/IGF-1 pathway and exemplify modulation of ghrelin signaling as an approach to mechanistic treatment of multiple age-related diseases by virtue of its ability to regulate key metabolic functions.
Keywords: IGF-1 receptor, Ghrelin, GHSR-1a knockouts, advanced glycation end products, Alzheimer Disease
Current Alzheimer Research
Title: Insulin Resistance, Glycemic Control and Adiposity: Key Determinants of Healthy Lifespan
Volume: 4 Issue: 2
Author(s): Peter S. DiStefano, Rory Curtis and Bradley J. Geddes
Affiliation:
Keywords: IGF-1 receptor, Ghrelin, GHSR-1a knockouts, advanced glycation end products, Alzheimer Disease
Abstract: Identification of genes and pathways that alter lifespan has allowed for new insights into factors that control the aging process as well as disease. While strong molecular links exist between aging and metabolism, we hypothesize that targeting the mechanisms involved in aging will also give rise to therapeutics that treat other devastating age-related diseases, such as neurodegeneration, cancer, inflammation and cardiovascular disease. Insulin sensitivity, glycemic control and adiposity are not only hallmarks of the major metabolic diseases, type 2 diabetes and obesity, but they also represent significant risk factors for the development of Alzheimers Disease and cognitive impairment. Insulin/IGF-1 signaling is an important pathway regulating aging and disease in a variety of species, including mammals. Here we describe an important role for the gut-derived peptide ghrelin in upstream signaling through the insulin/IGF-1 pathway and exemplify modulation of ghrelin signaling as an approach to mechanistic treatment of multiple age-related diseases by virtue of its ability to regulate key metabolic functions.
Export Options
About this article
Cite this article as:
DiStefano S. Peter, Curtis Rory and Geddes J. Bradley, Insulin Resistance, Glycemic Control and Adiposity: Key Determinants of Healthy Lifespan, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362038
DOI https://dx.doi.org/10.2174/156720507780362038 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Other Proteins Involved in Parkinson's Disease and Related Disorders
Current Protein & Peptide Science Curcumin Prevents Brain Damage and Cognitive Dysfunction During Ischemic-reperfusion Through the Regulation of miR-7-5p
Current Neurovascular Research Assessing Everyday Activities Across the Dementia Spectrum with the Amsterdam IADL Questionnaire
Current Alzheimer Research A Short Review of Diffusion Models and their Possibilities to Enhance Imaging Biomarkers for Neurodegenerative Diseases
Current Medical Imaging Insulin-Degrading Enzyme: A Link Between Alzheimer’s and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Carbon Nano Tubes: Novel Drug Delivery System in Amelioration of Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies
Current Alzheimer Research A Decrease in the Cellular Phosphodiester to Phosphomonoester Lipid Ratio is Characteristic of HIV-1 Infection
Current HIV Research AtreMorine Treatment Regulates DNA Methylation in Neurodegenerative Disorders: Epigenetic and Pharmacogenetic Studies
Current Pharmacogenomics and Personalized Medicine HIV-1, HCV and Alcohol in the CNS: Potential Interactions and Effects on Neuroinflammation
Current HIV Research Synaptic Aging is Associated with Mitochondrial Dysfunction, Reduced Antioxidant Contents and Increased Vulnerability to Amyloid-β Toxicity
Current Alzheimer Research Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry New Approaches for the Treatment of Mental Disorders Comorbid with Inflammatory Diseases
Current Topics in Medicinal Chemistry Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer’s Disease
Current Alzheimer Research Dietary Salt and Disease Prevention: A Global Perspective
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Small Molecules that Promote Neurogenesis in vitro
Recent Patents on CNS Drug Discovery (Discontinued)